ZVRA vs. GBIO, DSGN, NCNA, GALT, SBTX, ABEO, GTHX, SKYE, RIGL, and OMER
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Generation Bio (GBIO), Design Therapeutics (DSGN), NuCana (NCNA), Galectin Therapeutics (GALT), Silverback Therapeutics (SBTX), Abeona Therapeutics (ABEO), G1 Therapeutics (GTHX), Skye Bioscience (SKYE), Rigel Pharmaceuticals (RIGL), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry.
Generation Bio (NASDAQ:GBIO) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.
Zevra Therapeutics has higher revenue and earnings than Generation Bio. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Generation Bio received 23 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 66.67% of users gave Generation Bio an outperform vote.
Generation Bio has a beta of 2.78, suggesting that its stock price is 178% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
In the previous week, Zevra Therapeutics had 5 more articles in the media than Generation Bio. MarketBeat recorded 6 mentions for Zevra Therapeutics and 1 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.78 beat Zevra Therapeutics' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media.
Generation Bio presently has a consensus target price of $8.00, indicating a potential upside of 145.40%. Zevra Therapeutics has a consensus target price of $19.50, indicating a potential upside of 325.76%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Generation Bio.
Generation Bio has a net margin of 0.00% compared to Generation Bio's net margin of -167.69%. Zevra Therapeutics' return on equity of -52.29% beat Generation Bio's return on equity.
95.2% of Generation Bio shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 20.8% of Generation Bio shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Generation Bio and Zevra Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
